옵션 체인은 다양한 행사가격과 만기일에 대한 ENDRA Life Sciences의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 ENDRA Life Sciences에 대한 시장 심리를 평가합니다..

ENDRA Life Sciences (NASDAQ:NDRA) 주식, 옵션 체인

ENDRA Life Sciences

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

ENDRA Life Sciences Inc

News

CELZ

Creative Medical Technology Holdings Enters Agreements With Certain Warrant Holders For The Exercise Of Warrants, $3.7M Gross Proceeds

TORM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMD#NASDAQ">TRMD</a>) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $0.60 by 28.33 percent. This is a 63.51 percent decrease over earnings of $2.11 per share from the same period last year. The company reported quarterly sales of $214.70 million which missed the analyst consensus estimate of $257.00 million by 16.46 percent. This is a 44.64 percent decrease over sales of $387.79 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

TRMD

TORM Q4 EPS $0.77 Beats $0.60 Estimate, Sales $214.70M Miss $257.00M Estimate

CERO

CERo Therapeutics Executes Agreement With Contract Research Organization CellCarta To Manage Translational Assays For Phase 1 Clinical Trial  Of CER-1236 In Acute Myeloid Leukemia

WIIM

Kodiak Gas Services shares are trading lower after the company reported worse-than-expected Q4 financial results.

B of A Securities analyst Bradley Sills maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and lowers the price target from $420 to $286.

Price Target

Analyst Ratings

B of A Securities Maintains Buy on MongoDB, Lowers Price Target to $286

RGTI

Rigetti Computing shares are trading lower following a Q4 revenue miss.

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and raises the price target from $6 to $7.

OCGN

Chardan Capital Maintains Buy on Ocugen, Raises Price Target to $7

Contracts

KTOS

Naval Air Systems Command Awards Kratos Additional $59.3M For BQM-177A Subsonic Aerial Target Systems

Management

Masco Corporation CEO Keith Allman To Retire, Jonathon Nudi To Be Appointed PREsident And CEO Effective Jul. 7

B of A Securities analyst Vivek Arya maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and lowers the price target from $150 to $120.

MRVL

B of A Securities Maintains Buy on Marvell Tech, Lowers Price Target to $120

Macro Economic Events

Global

Economics

ECB Cuts Deposit Facility Rate From 2.75% To 2.5%, Cuts Refi Rate From 2.9% To 2.65%

Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) shares are trading higher in the <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket session on Thursday</a>.
The company reported fourth-quarter adjusted earnings per share of $4.13, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44161791/burlington-stores-inc-reports-fourth-quarter-and-full-year-2024-earnings" rel="noreferrer noopener">beating the street view of $3.76.</a>
Quarterly sales of $3.28 billion (+5% year over year) outpaced the analyst consensus estimate of $3.23 billion. Comparable store sales growth for the quarter was 6%, versus&nbsp;guidance&nbsp;of&nbsp;0%&nbsp;to&nbsp;2%.
&#8220;Taking 2024 as a whole, total sales increased 11%, comparable store sales increased 4%, and Adjusted EBIT Margin increased 100 basis points,&#8221; said Michael O&#8217;Sullivan, CEO.&nbsp;
The quarterly gross profit was $1.404 billion, up from $1.333 billion in the year-ago period. Gross margin expanded by 30 basis points to 42.9%, freight improved by 20 basis points, and merchandise margin increased by 10 basis points.
Adjusted EBITDA&nbsp;was $456 million in the quarter under review, higher than $412 million in the year-ago period.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44161401/rio-tintos-1-8-billion-iron-ore-expansion-ramps-up-in-australia-details" rel="noreferrer noopener"> Rio Tinto&#8217;s $1.8 Billion Iron Ore Expansion Ramps Up In Australia: Details</a>
&#8220;We opened 101 net new stores in 2024 and relocated 31 of our older oversized locations,&#8221; the CEO added.
The company ended the fourth quarter with $1.822 billion in liquidity, comprised of $995 million in unrestricted cash.
Outlook: &#8220;The outlook for 2025 is very uncertain and we will plan and manage our business accordingly,&#8221; the CEO said.
The company expects total sales to increase by 6% &#8211; 8%, on top of the 11% increase the prior year. The company sees adjusted EPS of $8.70 &#8211; $9.30 (estimate: $9.43).
Burlington expects first-quarter total sales to increase 5% &#8211; 7%, comparable store sales are expected to be flattish. The company sees adjusted EPS of $1.30 &#8211; $1.45 (estimate: $1.68).
Price Action: BURL shares are trading higher by 12.5% to $266.50 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/forex/25/03/44161314/us-stocks-likely-to-open-lower-after-wednesdays-blip-be-patient-but-be-ready-to-act-says-analyst-as-market-uncertainties-can-create-opportunities" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Lower After Wednesday&#8217;s Blip: &#8216;Be Patient, But Be Ready To Act,&#8217; Says Analyst As Market Uncertainties Can Create &#8216;Opportunities&#8217;</a></li>
</ul>
Photo via Shutterstock.

Equities

Guidance

Markets

Movers

General

BURL

Burlington Stock Jumps As Q4 Earnings Crush Estimates, But CEO Warns Of 'Uncertain' 2025 Outlook

RYAAY

Ryanair shares are trading lower after Morgan Stanley downgraded its rating on the stock from overweight to equal weight.

ADTX

Aditxt'ss Adimune Subsidiary To Ship Drug Substances For Final Drug Product Formulation Of ADI-100 Ahead Of Planned Trials For Type 1 Diabetes And Psoriasis In Germany And Stiff Person Syndrome At Mayo Clinic

B of A Securities analyst Peter Galbo maintains Campbell`s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) with a Underperform and lowers the price target from $45 to $41.

B of A Securities Maintains Underperform on Campbell's, Lowers Price Target to $41

Small Cap Consumer Research analyst Eric Beder reiterates Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) with a Buy and maintains $5.5 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Vera Bradley, Maintains $5.5 Price Target

VRME

VerifyMe shares are trading lower after the company reported worse-than-expected Q4 earnings and sales.

MRAM

Everspin Awarded $10.5M Contract For MRAM IP And Foundry Services For Purdue University's ME Commons In-Memory Compute Project

Baird analyst Shrenik Kothari maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $240 to $250.

Baird Maintains Outperform on Zscaler, Raises Price Target to $250

VYNE

VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate

Press Releases

ENDRA Life Sciences Announces Leadership Changes

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

ENDRA Life Sciences Announces Reverse Stock Split

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Comments

ENDRA Life Sciences

ENDRA Life Sciences (NDRA) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌